The biotechnology firm has raised $20.1m in series C funding one week after filing for an initial public offering, taking its overall financing to $68.1m.
One week after filing for an initial public offering (IPO), US-based biotechnology firm Verastem has secured a further $20.1m in a series C round of funding. The financing was filed for on 10th November.
Verastem has not disclosed the investors from the latest round, however the backers were all previous investors in Verastem, having participated in Verastem’s $32m series B round in July.
According to information on the IPO filing, the largest shareholders in Verastem are venture capital (VC)…
